

APPROPRIATE USE OF IV PANTOPRAZOLE (PROTONIX) (C1), Esther Chen, Alpesh Amin, Debra Kawaguchi, Amy Schatzman. University of CA, Irvine Medical Center, Orange, CA (egchen@uci.edu) IRB approval received.

There has been growing concern that IV proton pump inhibitors are used inappropriately in many institutions, leading to increased cost and suboptimal patient care. Several institutions have conducted studies finding that IV proton pump inhibitors are often used for an inappropriate indication or duration. At University of CA, Irvine Medical Center, pantoprazole, the IV proton pump inhibitor of choice, has been the most frequently prescribed IV medication, with an estimated 19,344 doses ordered in the last fiscal year. The authors of this project have hypothesized that many of the doses prescribed were not appropriate and that by reviewing the use of IV pantoprazole in the last fiscal year, the institution will have the tools to begin realizing cost savings. Thus, the aim of this project is to optimize the use of IV pantoprazole at this institution. Methods include 1) developing criteria for IV pantoprazole use based on literature; 2) conducting a retrospective chart review of adult inpatients who received IV pantoprazole in the last fiscal year in order to determine if the medication was used according to criteria; 3) projecting the potential cost savings of replacing IV pantoprazole with the appropriate therapy or no acid suppression therapy if not indicated, in each patient case; 4) developing and implementing formal guidelines for IV

pantoprazole use at University of CA, Irvine Medical Center. Results and conclusions will be presented.